Waltermire Robert E.
Officer at MDGL
- Sold, on record
- $11.3M
- Dollars the filings state
- Form 4 sales
- 10
- Latest Mar 5, 2025
- Form 144 notices
- 6
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- MDGLMADRIGAL PHARMACEUTICALS, INC.Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale MDGLNo planJan 17, 2025 2025
Sold 442 shares at $273.41 ($121k)
Waltermire Robert E., Senior VP, Chief Pharma Dev.
No 10b5-1 planSold 8% of holdings ($1.5M position)5,058 shares left0.2x usual sizeFollows a Form 144Filing
- 2 Form 144 notice MDGLNoticeJan 17, 2025 same day
Filed to sell 442 shares ($121k)
Waltermire Robert E., Officer
No 10b5-1 plan0.2x usual sizeFiling
- 3 Form 144 notice MDGLNoticeJan 24, 2025 +7 days
Filed to sell 103 shares ($35k)
Waltermire Robert E., Officer
No 10b5-1 plan0.1x usual sizeFiling
- 4 Form 4 sale MDGLNo planJan 24, 2025 same day
Sold 103 shares at $335.24 ($35k)
Waltermire Robert E., Senior VP, Chief Pharma Dev.
No 10b5-1 planSold 2% of holdings ($1.7M position)4,955 shares left0.1x usual sizeFollows a Form 144Filing
- 5 Form 144 notice MDGLNoticeFeb 28, 2025 +35 days
Filed to sell 1,227 shares ($418k)
Waltermire Robert E., Officer
No 10b5-1 plan0.6x usual sizeFiling
- 6 Form 4 sale MDGLNo planFeb 28, 2025 same day
Sold 1,227 shares at $341.07 ($418k)
Waltermire Robert E., Senior VP, Chief Pharma Dev.
No 10b5-1 planSold 24.8% of holdings ($1.7M position)3,728 shares left0.6x usual sizeFollows a Form 144Filing
- 7 Form 144 notice MDGLNoticeMar 5, 2025 +5 days
Filed to sell 14,113 shares ($4.8M)
Waltermire Robert E., Officer
No 10b5-1 plan9x usual sizeFiling
- 8 Form 4 sale MDGLUnusualMar 5, 2025 same day
Sold 14,113 shares at $341.33 ($4.8M)
Waltermire Robert E., Senior VP, Chief Pharma Dev.
No 10b5-1 planSold 79.1% of holdings ($6.1M position)3,728 shares left9x usual sizeFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (16)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2025 | Mar 7, 2025 | MDGL | Senior VP, Chief Pharma Dev. | Form 4 sale | 14,113 | $4.8M | 79.1% | Unusual | SEC |
| Mar 5, 2025 | Mar 5, 2025 | MDGL | Officer | Form 144 notice | 14,113 | $4.8M | Notice | SEC | |
| Feb 28, 2025 | Mar 4, 2025 | MDGL | Senior VP, Chief Pharma Dev. | Form 4 sale | 1,227 | $418k | 24.8% | No plan | SEC |
| Feb 28, 2025 | Feb 28, 2025 | MDGL | Officer | Form 144 notice | 1,227 | $418k | Notice | SEC | |
| Jan 24, 2025 | Jan 27, 2025 | MDGL | Senior VP, Chief Pharma Dev. | Form 4 sale | 103 | $35k | 2.0% | No plan | SEC |
| Jan 24, 2025 | Jan 24, 2025 | MDGL | Officer | Form 144 notice | 103 | $35k | Notice | SEC | |
| Jan 17, 2025 | Jan 17, 2025 | MDGL | Officer | Form 144 notice | 442 | $121k | Notice | SEC | |
| Jan 17, 2025 | Jan 17, 2025 | MDGL | Senior VP, Chief Pharma Dev. | Form 4 sale | 442 | $121k | 8.0% | No plan | SEC |
| Jun 14, 2024 | Jun 18, 2024 | MDGL | Senior VP, Chief Pharma Dev. | Form 4 sale | 1,900 | $532k | 25.7% | Unusual | SEC |
| Jun 14, 2024 | Jun 14, 2024 | MDGL | Officer | Form 144 notice | 1,900 | $532k | Notice | SEC | |
| Jun 12, 2024 | Jun 14, 2024 | MDGL | Senior VP, Chief Pharma Dev. | Form 4 sale | 2,000 | $570k | 26.7% | Unusual | SEC |
| Jun 12, 2024 | Jun 12, 2024 | MDGL | Officer | Form 144 notice | 6,000 | $1.7M | Notice | SEC | |
| May 21, 2024 | May 23, 2024 | MDGL | Senior VP, Chief Pharma Dev. | Form 4 sale | 1,036 | $240k | 15.9% | No plan | SEC |
| Dec 15, 2023 | Dec 18, 2023 | MDGL | Senior VP, Chief Pharma Dev. | Form 4 sale | 4,000 | $942k | 41.4% | Unusual | SEC |
| Dec 13, 2023 | Dec 14, 2023 | MDGL | Senior VP, Chief Pharma Dev. | Form 4 sale | 3,800 | $847k | 40.1% | Unusual | SEC |
| Mar 1, 2023 | Mar 2, 2023 | MDGL | Senior VP, Chief Pharma Dev. | Form 4 sale | 10,000 | $2.7M | 63.8% | Unusual | SEC |